NEUROGENE INC (NGNE) Stock Price, Quote, News and Overview
NASDAQ:NGNE - Nasdaq - US64135M1053 - Common Stock - Currency: USD
NGNE Quote, Performance and Key Statistics
17.36
+0.05 (+0.29%)
The current stock price of NGNE is 17.36 USD. In the past month the price increased by 11.42%. In the past year, price decreased by -42.42%.
NGNE Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About NGNE
Company Profile
Neurogene, Inc. is a clinical-stage biotechnology company, which engages in the development of product portfolio of genetic medicines for rare neurological diseases. The company is headquartered in New York City, New York and currently employs 91 full-time employees. The company went IPO on 2014-03-07. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is under development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. NGN-401 is being evaluated in pediatric female patients with Rett syndrome in a Phase 1/2 open-label, multi-center clinical trial that assesses the safety, tolerability, and efficacy of two doses of NGN-401 delivered using a one-time intracerebral ventricular (ICV) procedure. The company is also developing NGN-101 for the treatment of CLN5 Batten disease.
Company Info
NEUROGENE INC
535 W 24Th Street, 5Th Floor
New York City NEW YORK US
Employees: 91
Company Website: https://www.neurogene.com/
Investor Relations: http://investor.aqxpharma.com/
Phone: 18772375020
NEUROGENE INC / NGNE FAQ
What is the stock price of NEUROGENE INC today?
The current stock price of NGNE is 17.36 USD. The price increased by 0.29% in the last trading session.
What is the ticker symbol for NEUROGENE INC stock?
The exchange symbol of NEUROGENE INC is NGNE and it is listed on the Nasdaq exchange.
On which exchange is NGNE stock listed?
NGNE stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for NEUROGENE INC stock?
13 analysts have analysed NGNE and the average price target is 53.86 USD. This implies a price increase of 210.23% is expected in the next year compared to the current price of 17.36. Check the NEUROGENE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is NEUROGENE INC worth?
NEUROGENE INC (NGNE) has a market capitalization of 257.80M USD. This makes NGNE a Micro Cap stock.
How many employees does NEUROGENE INC have?
NEUROGENE INC (NGNE) currently has 91 employees.
What are the support and resistance levels for NEUROGENE INC (NGNE) stock?
NEUROGENE INC (NGNE) has a support level at 15.06 and a resistance level at 22.54. Check the full technical report for a detailed analysis of NGNE support and resistance levels.
Should I buy NEUROGENE INC (NGNE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of NGNE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of NGNE, evaluating the profitability, health, valuation and growth aspects
- NEUROGENE INC (NGNE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- NEUROGENE INC (NGNE) Sales and EPS estimates to see what analysts future expectations are.
- NEUROGENE INC (NGNE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- NEUROGENE INC (NGNE) Insider and Institutional Ownership to learn about the owners and their transactions.
- NEUROGENE INC (NGNE) Stock Chart to make your own analysis
- NEUROGENE INC (NGNE) Latest news and press-releases to stay up to date.
Does NEUROGENE INC (NGNE) stock pay dividends?
NGNE does not pay a dividend.
When does NEUROGENE INC (NGNE) report earnings?
NEUROGENE INC (NGNE) will report earnings on 2025-03-17, after the market close.
What is the Price/Earnings (PE) ratio of NEUROGENE INC (NGNE)?
NEUROGENE INC (NGNE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.79).
What is the Short Interest ratio of NEUROGENE INC (NGNE) stock?
The outstanding short interest for NEUROGENE INC (NGNE) is 14.97% of its float. Check the ownership tab for more information on the NGNE short interest.
NGNE Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to NGNE. When comparing the yearly performance of all stocks, NGNE is a bad performer in the overall market: 89.69% of all stocks are doing better.
NGNE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NGNE. NGNE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
NGNE Financial Highlights
Over the last trailing twelve months NGNE reported a non-GAAP Earnings per Share(EPS) of -4.79. The EPS increased by 67.51% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -43.34% | ||
| ROE | -51.76% | ||
| Debt/Equity | 0 |
NGNE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 88% to NGNE. The Buy consensus is the average rating of analysts ratings from 13 analysts.